Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Drug Discovery & Development

Kattesh V. Katti's Biography



Kattesh V. Katti, Director, Institute of Green Nanotechnology / Radiology / Cancer Nanotechnology Platform, University of Missouri

Professor Kattesh V. Katti is internationally recognized as a leader in the interconnecting fields of—chemistry, radiopharmaceutical sciences, nanotechnology/green nanotechnology and nanomedicine—for biomedical applications, specifically for molecular imaging and therapy of living subjects. The impact of Dr. Katti’s work is widespread, as his pioneering discoveries and strategies, originally developed in his laboratory in bioconjugate chemistry and Nanomedicine, and green nanotechnological tools, are used in many laboratories, industries and hospitals around the world. His contributions in nano and green nanotechnologies have already created a transformative progress in nanomedicine by aiding molecular imaging to help diagnose and manage therapy—all at the cellular levels. Dr. Katti’s ground breaking discoveries in green nanotechnology where he has demonstrated that biocompatible nanoparticles can be produced without the intervention of any toxic chemicals, through phytochemicals of high antioxidant capacities and tumor receptor specificities have created a new generation of molecular imaging and therapeutic nanoceuticals. His approach to green nanotechnology has furthered the scope of holistic and integrative medicine with implications in modulating signaling pathways allowing optimization of therapies targeted to tumor cells/regions without causing adverse toxic effects to normal cells. These original discoveries are expected to have a major impact on how molecular imaging and therapies will eventually be individualized to allow their greater success through theranostic approaches using radioactive nanoparticles, photothermal therapy using targeted nanoparticles and novel therapies involving phytochemicals. Myriad of such approaches developed by Dr. Katti are already impacting clinical translation through comparative oncology in realistic ways as new drugs are being validated for their efficacy in imaging and therapy using tumor bearing dogs where the disease mimics human conditions. In recognition of his original contributions, Dr. Katti has been awarded a number of international awards and citations which include: International Hevesy Medal Award (2015) for excellence in Nuclear Sciences; Elected to the fellowship of the National Academy of Inventors (2015); One of the ‘25 Most Influential Scientists In Molecular Imaging in the World’ award by RT Image, the ‘Father of Green Nanotechnology’ citation by the Nobel Prize Winner Norman Borlaug, Gauss Professorship—Hall of Fame—from the Gottingen Academy of Sciences, ‘Outstanding Scientists Fellows’ award and induction as a Fellow of the Academy of Science, St Louis—one of the oldest scientific academies of the world and many more. In 2013, Dr. Katti was elected as a fellow of the American Association for the Advancement of Science with a citation “for distinguished contributions encompassing nanoscale chemistry, particularly for ground breaking discoveries enabling application of nanotechnology concepts for biomedical applications”. His unprecedented discovery of the production of tumor specific gold nanoparticles through 100% green processes have been cited as the Editor’s choice in Nature, Future Medicine, in Science (AAAS), in Popular Science, by the Discovery Channel and have been highlighted in scientific/medical programs of the British Broadcasting Corporation (BBC, London).

Kattesh V. Katti Image

Green Nanotechnology Approaches in Drug Discovery: Implications in Controlling Primary and Metastatic Tumours

Tuesday, 30 October 2012 at 09:00

Add to Calendar ▼2012-10-30 09:00:002012-10-30 10:00:00Europe/LondonGreen Nanotechnology Approaches in Drug Discovery: Implications in Controlling Primary and Metastatic TumoursSELECTBIOenquiries@selectbiosciences.com

This presentation will discuss novel Green Nanotechnology approaches in drug discovery with direct implications in treating various forms of solid tumors. Development of Laminin receptor specific EGCg-AuNPs and their  therapeutic efficacy in treating prostate tumors will be presented. The dual role of EGCG in offering target specificity and as an effective DNA methylation inhibitor will also be presented. 


Add to Calendar ▼2012-10-30 00:00:002012-10-31 00:00:00Europe/LondonDrug Discovery and DevelopmentSELECTBIOenquiries@selectbiosciences.com